Early Alert: Boston Scientific ENDOTAK RELIANCE Defibrillation Leads — investigative report, clinical guidance, and manufacturer action plan

Source: FDA Early Alert (posted Aug 6, 2025). U.S. Food and Drug Administration

Executive summary (two sentences)

The FDA posted an Early Alert after Boston Scientific notified clinicians that certain ENDOTAK RELIANCE defibrillation leads with ePTFE-coated shock coils are showing coil calcification that correlates with a gradual rise in low-voltage shock impedance (LVSI) and can reduce shock efficacy — a failure mode linked to hundreds of serious injuries and deaths. The agency is monitoring the issue and clinicians are advised to follow the company’s physician letter for trending LVSI/HVSI and individualized management; Boston Scientific and health systems must urgently pursue root-cause, labeling, programming, and surveillance fixes. U.S. Food and Drug Administration

What the FDA posted — the core facts

Affected devices: Multiple ENDOTAK RELIANCE lead models (many model numbers listed in the FDA alert) with expanded-PTFE (ePTFE) coated shock coils. U.S. Food and Drug Administration
Problem identified: Calcification of the ePTFE shock coil encapsulant can biologically encapsulate and electrically insulate coil(s), producing a pattern of gradually rising LVSI and reduced delivered shock effectiveness. U.S. Food and Drug Administration
Clinical impact: The most common harm reported is early lead replacement; the gravest outcomes include failed defibrillation during ventricular arrhythmia, cardiac resuscitation, and death. As of July 24, Boston Scientific reported 386 serious injuries and 16 patient deaths associated with this phenomenon. U.S. Food and Drug Administration
When it shows up: The LVSI trend tends to be late-manifesting, often eight or more years after implant, and may not be immediately evident without trending analysis. U.S. Food and Drug Administration
FDA action: This is an Early Alert under the FDA’s Communications Pilot to speed public awareness; the FDA is reviewing data and will update as warranted. It is not (yet) a formal recall on the FDA page, but the issue is high risk and Boston Scientific has issued guidance to clinicians. U.S. Food and Drug Administration

Why this is concerning (technical & clinical implications)

ePTFE calcification electrically insulates the coil. Insulation increases impedance; higher impedance reduces energy delivered to myocardial tissue for a given device output, thereby lowering the probability of successful defibrillation. The effect can be intermittent and progressive, complicating detection. U.S. Food and Drug Administration
Trending (not single-value checks) is required. Single impedance checks or spot testing after a shock can transiently lower impedance and mask long-term trends — the FDA/Boston Scientific guidance therefore focuses on the 28-day average LVSI and review of high-voltage shock impedance (HVSI) across recent episodes. U.S. Food and Drug Administration
Programming choices matter. Boston Scientific notes a polarity bias — systems programmed to Reversed (RV+) polarity are more likely to have elevated HVSI alerts and lower shock success rates than Initial (RV−) polarity. This creates a programmable mitigation lever (and a potential field-fix). U.S. Food and Drug Administration
Extraction risk vs. abandonment trade-off. Leads with calcified coils may be heavily adherent; extraction can carry significant procedural risk. Clinicians must weigh extraction vs. abandonment on a per-patient basis. U.S. Food and Drug Administration

Clinical guidance — what hospitals and cardiology teams should do now

(Adapted from Boston Scientific’s physician letter and FDA alert)

Continue routine in-person or remote monitoring, but add trending analytics: determine the most recent approximate 28-day average low-voltage shock impedance (LVSI) that is not influenced by delivered shocks, and review HVSI for shocks since last check. Use the physician letter’s criteria. U.S. Food and Drug Administration
Flag leads implanted ≥8 years for prioritized review and trending. These leads are more likely to exhibit calcification-related LVSI rise. U.S. Food and Drug Administration
Assess polarity programming. Review whether systems are programmed RV+ and consider the clinical rationale for polarity choice; RV+ shocks had higher HVSI alert rates. Polarity change is a potential short-term mitigation but must be balanced with pacing/therapy considerations. U.S. Food and Drug Administration
If lead replacement is considered, carefully evaluate extraction risks: calcified coils may increase extraction morbidity; in many cases abandonment may be safer. Discuss in multidisciplinary teams and document shared decision-making. U.S. Food and Drug Administration
Report events. Submit all device malfunctions, injuries, or deaths to FDA MedWatch and to Boston Scientific technical services. Timely reporting improves signal characterization. U.S. Food and Drug Administration

Investigative questions reporters / hospital QA teams should pursue

Is calcification clustered by implant lot, device manufacturing period, or geographic cohort (e.g., water chemistry, anticoagulation practices, comorbidities)? U.S. Food and Drug Administration
What histopathologic mechanism links ePTFE encapsulant to calcification in vivo (biofilm, inflammatory response, mineral deposition)? U.S. Food and Drug Administration
Are there device design or material alternatives that retain coil performance without long-term calcification? U.S. Food and Drug Administration

What the FDA has done (and not done)

Posted an Early Alert to raise clinician/hospital awareness immediately and to accelerate reporting while the agency reviews the data. This is part of a pilot to speed up communications for potentially high-risk device issues. The FDA is monitoring and will post updates; the page explicitly instructs users to follow Boston Scientific’s letter and to check the FDA page for updates. It is not a formal nationwide recall notice on this page, though Boston Scientific has issued customer letters and technical guidance. U.S. Food and Drug Administration

What Boston Scientific (manufacturer) needs to consider and revise — an action plan

Immediate operational & communications actions (days → weeks)

Expand clinician outreach — issue clear Dear HCP and Patient letters, make the physician letter widely available, and ensure technical services and field teams can support complex case reviews. Provide patient letters on request for disclosure/consent. U.S. Food and Drug Administration
Provide analytic tools — publish recommended algorithms or scripts for EMR/remote-monitoring platforms to calculate 28-day LVSI trends and flag concerning trajectories. Offer to run batch analyses for large centers. U.S. Food and Drug Administration
Triage inventory & implants — identify patients with affected models and long implant duration; prioritize high-risk patients (history of ventricular arrhythmia, intolerance to lead abandonment). U.S. Food and Drug Administration

Engineering & design actions (weeks → months)

Root-cause & materials science investigation — perform explant analysis, histology, and surface chemistry to confirm how and why ePTFE coating calcifies; test alternative encapsulants/coatings and assess long-term in-vitro calcification propensity. U.S. Food and Drug Administration
Accelerated aging & implantation simulation — run mechanical/chemical aging and simulated implant conditions to reproduce calcification and validate any design fixes. U.S. Food and Drug Administration
Software mitigations — develop device/monitor firmware updates (where feasible) to detect rising LVSI patterns early, generate actionable clinician alerts (e.g., trend slope thresholds), and recommend programming adjustments (polarity) as interim measures. U.S. Food and Drug Administration

Regulatory, quality systems & compliance (immediate → ongoing)

Engage FDA proactively — submit root-cause findings and CAPA plans, and update the agency frequently. Be prepared for possible field safety corrective actions or recalls depending on findings. U.S. Food and Drug Administration
Revise labeling / IFU — add specific instructions on LVSI trending, recommended monitoring frequency for older implants, programming considerations (polarity), and extraction risk language. Ensure UDI traceability is emphasized for adverse-event correlations. U.S. Food and Drug Administration
Strengthen postmarket surveillance — implement targeted active surveillance (registry or sentinel cohorts) to quantify observed vs expected defibrillation failure rates and to follow outcomes of extraction vs abandonment strategies. U.S. Food and Drug Administration

Clinical support & medico-legal (weeks → months)

Create multidisciplinary advisory panels (electrophysiology, cardiac surgery, materials science) and publish interim consensus guidance to assist clinicians in real-time decisions. U.S. Food and Drug Administration
Prepare reimbursement / patient support plans — for patients needing lead revision or prolonged monitoring, coordinate payer discussions and offer logistical/financial assistance where appropriate. U.S. Food and Drug Administration

Risk communication — what to tell patients (plain language)

For patients with an ENDOTAK RELIANCE lead: “Your device may develop hardening (calcification) on a coil that can increase electrical resistance and reduce the effectiveness of shocks. Your clinic will check your device trends and advise if further action is needed. Do not make changes on your own; contact your heart-rhythm team if you feel faint, have palpitations, or lose consciousness.” U.S. Food and Drug Administration

Quick reference table

Topic	Key point
Affected device	ENDOTAK RELIANCE defibrillation leads with ePTFE-coated coils (multiple model numbers). U.S. Food and Drug Administration
Failure mode	Coil calcification → gradually rising LVSI → potential reduction in shock efficacy. U.S. Food and Drug Administration
Reports (to date)	Boston Scientific reported 386 serious injuries and 16 deaths as of July 24. U.S. Food and Drug Administration
Clinical action	Trend 28-day LVSI not influenced by shocks; review HVSI; consider polarity/programming and extraction vs abandonment decisions. U.S. Food and Drug Administration
FDA action	Early Alert (Communications Pilot); FDA reviewing information and will update web page as new info becomes available. U.S. Food and Drug Administration

Final assessment & recommended next steps (for hospital QA / the manufacturer)

Hospitals: implement immediate trending checks for all patients with ENDOTAK RELIANCE leads, document decisions in the medical record, and prioritize high-risk patients for review. Report adverse events to MedWatch. U.S. Food and Drug Administration
Manufacturer (Boston Scientific): accelerate root-cause analysis, provide trend-detection tools and clear clinical decision aids, update labeling/IFU, and work with FDA on CAPA or corrective action (including field safety notices, registry studies, and potential recalls if material defect is confirmed). U.S. Food and Drug Administration

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.